Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Diagnostic Value and Biological Significant of cd71 in Lymphoid Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03720977
Recruitment Status : Not yet recruiting
First Posted : October 26, 2018
Last Update Posted : October 26, 2018
Sponsor:
Information provided by (Responsible Party):
Marwa Aboelim Shafeik, Assiut University

Tracking Information
First Submitted Date October 18, 2018
First Posted Date October 26, 2018
Last Update Posted Date October 26, 2018
Estimated Study Start Date December 1, 2019
Estimated Primary Completion Date December 1, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 24, 2018)
determin diagnostic value of cd71 in lymphoid disorder [ Time Frame: baseline ]
Routine investigations for diagnosis: CBC. Bone marrow aspiration morphology. Cytochemistry. Flow cytometry immunophenotyping. Bone marrow biopsy when indicated. Special investigation is flow cytometry examination of CD71 expression. total sample size 79 person .sample will be collected from patient in hospital university ,Data will be analysed by SPSS program it is growth receptor is expressed on activated B and T cells, macrophages, reticulocytes, erythroid precursors, and malignant tissues
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Diagnostic Value and Biological Significant of cd71 in Lymphoid Disorders
Official Title Diagnostic Value and Biological Significant of cd71 in Lymphoid Dis Order
Brief Summary CD71 is expressed on activated B and T cells, macrophages, reticulocytes, erythroid precursors, and malignant tissues. , reflecting the requirement for iron in hemoglobin. , CD71 expression is upregulated on immature proliferating cells and low levels on resting mature lymphocytes. In addition to this general function, CD71 appears to play a costimulatory role in T cell activation and receptor for IgA1 antibodies So it is growth receptor that may help in diagnosis of lymphoid disorder and in differentiation of malignant and benign that will be studied investigate CD71 expression in lymphoid disorders and its diagnostic value ,we from collect data patient and do rotune examination
Detailed Description
  1. Routine investigations for diagnosis:

    • CBC.
    • Bone marrow aspiration morphology.
    • Cytochemistry.
    • Flow cytometry immunophenotyping.
    • Bone marrow biopsy when indicated.
  2. Special investigation is flow cytometry examination of CD71 expression.

sample size calculation ; sample size cases 39 sample size controls 39 total sample size 79 sample will be collected from patient in hospital university ,Data will be analysed by SPSS program

Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population confidence level 95 sample size 139
Condition
  • Lyphoid Disorders
  • cd71
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Not yet recruiting
Estimated Enrollment
 (submitted: October 24, 2018)
139
Original Estimated Enrollment Same as current
Estimated Study Completion Date December 1, 2020
Estimated Primary Completion Date December 1, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • all patients wiil be diagnosed lymphoid disorders

Exclusion Criteria:

  • not present
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts
Contact: Marwa Aboelim 01012636292 marwaaboelim@gmail.com
Contact: Tagreed kamal, dr 01002286687
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03720977
Other Study ID Numbers diagnostic value of cd71
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Plan Description: immunophenotyping by flow cytometry of cd71
Responsible Party Marwa Aboelim Shafeik, Assiut University
Study Sponsor Marwa Aboelim Shafeik
Collaborators Not Provided
Investigators
Study Director: Maged Salah, Prof Assiut University .clinical pathologydepartment
PRS Account Assiut University
Verification Date October 2018